Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 29;13(4):493.
doi: 10.3390/metabo13040493.

Effects of Hypolipidemic Drugs on Psoriasis

Mateusz Matwiejuk  1 , Hanna Mysliwiec  1 , Olivia Jakubowicz-Zalewska  1 , Adrian Chabowski  2 , Iwona Flisiak  1
Affiliations
Review

Effects of Hypolipidemic Drugs on Psoriasis

Mateusz Matwiejuk et al. Metabolites. .

Abstract

Psoriasis is a chronic, systematic, inflammatory disease in which multiple metabolic and immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic syndrome, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease, and numerous metabolic disorders. In clinical practice, the most commonly used drugs in the treatment of lipid abnormalities are statins and fibrates. Statins are characterized by pleiotropic effects such as antioxidant, anti-inflammatory, anticoagulant, and antiproliferative. They work by reducing the concentrations of low-density lipoprotein (LDL), total cholesterol, and triglycerides and stabilizing atherosclerotic plaque. Fibrates are medications, which help to lower triglycerides, LDL, very low-density lipoprotein (VLDL) levels and increase lower high-density lipoprotein (HDL). In recent years, many new drugs were found to normalize the lipid profile in patients with psoriasis: glitazones (pioglitazone, troglitazone), and glucagon-like peptide-1 (GLP-1) receptor agonists. Pioglitazone improves the lipid profile, including the decrease of triglycerides, fatty acids, and LDL, as well as the increase of HDL. Glucagon-like peptide 1 (GLP-1) analogs decrease modestly low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides. The purpose of this study is to assess the current state of knowledge on the effect of different hypolipidemic treatments on the course of psoriasis. The study includes literature from medical databases PubMed and Google Scholar. We were browsing PubMed and Google Scholar until the beginning of December. The systematic review includes 41 eligible original articles.

Keywords: GLP-1 analogs; PCSK9 inhibitors; fibrates; glitazones; psoriasis; statins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The search process.
Figure 2
Figure 2
Major pharmacological effects of statins.
See this image and copyright information in PMC

References

    1. Trong H.N., Tat T.N., Anh T.T.N., Uyen N.P., Van T.N., Hau K.T., Gandolfi M., Satolli F., Feliciani C., Tirant M., et al. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis. Open Access Maced. J. Med. Sci. 2019;7:237–242. doi: 10.3889/oamjms.2019.060. - DOI - PMC - PubMed
    1. Imamura T., Takata I., Ogasawara M., Matsutani Y., Yamamoto T., Asagami C. Clofibrate treatment of psoriasis with hypertriglycemia-clinical, histological and laboratory analysis. Nihon Hifuka Gakkai Zasshi. 1991;101:623–628. - PubMed
    1. Singh S., Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort) BMC Dermatol. 2016;16:12. doi: 10.1186/s12895-016-0049-y. - DOI - PMC - PubMed
    1. Xu X., Lin L., Chen P., Yu Y., Chen S., Chen X., Shao Z. Treatment with liraglutide, a glucagon-like peptide-1 analogue, imporves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res. Clin. Pract. 2019;150:167–173. doi: 10.1016/j.diabres.2019.03.002. - DOI - PubMed
    1. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Ann. Intern. Med. 2009;151:W65–W94. doi: 10.7326/0003-4819-151-4-200908180-00136. - DOI - PubMed